Pacific Edge

Pacific Edge ROCE

The Return on Capital Employed (ROCE) of Pacific Edge (PEB.NZ) as of Oct 23, 2026 is -121.79 %. In the previous year, Return on Capital Employed (ROCE) was -61.47 % — a change of 98.11% (lower).

ROCE

-121.79 %

YoY

98.11%

Last updated:

In 2025, Pacific Edge's return on capital employed (ROCE) was -121.79 %, a 98.11% increase from the -61.47 % ROCE in the previous year.

The Pacific Edge ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-120.22 NZD
Jan 1, 2019
-131.06 NZD
Jan 1, 2020
-131.71 NZD
Jan 1, 2021
-62.32 NZD
Jan 1, 2022
-18.92 NZD
Jan 1, 2023
-38.72 NZD
Jan 1, 2024
-61.47 NZD
Jan 1, 2025
-121.79 NZD
The Pacific Edge ROCE history
YEARROCEYoY
-121.79 %+98.11%
-61.47 %+58.78%
-38.72 %+104.61%
-18.92 %-69.64%
-62.32 %-52.68%
-131.71 %+0.49%
-131.06 %+9.02%
-120.22 %-21.58%
-153.30 %+137.36%
-64.59 %-47.88%
-123.91 %+178.22%
-44.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pacific Edge Stock analysis

What does Pacific Edge do? Pacific Edge Ltd is a company based in New Zealand specializing in the development and marketing of cancer diagnostic test systems. The company was founded in 2001 and has since become a leading provider of cancer detection systems in New Zealand and other countries. Pacific Edge's business model is based on the development and marketing of non-invasive diagnostic methods for early cancer detection. The tests offered are based on the analysis of urine samples, which are analyzed using state-of-the-art technologies to detect specific proteins in the urine that are typically associated with cancer. These tests enable doctors and patients to detect cancer at an early stage, increasing treatment and cure rates. Pacific Edge specializes in three main areas: urology, gynecology, and bladder cancer. The urology division focuses on the development of diagnostic tests for prostate cancer. It is one of the most common types of cancer in men, and early detection is known to increase the chance of a complete cure. Tests such as Cxbladder enable doctors to detect prostate cancer at an early stage. Pacific Edge's gynecology division focuses on the development of diagnostic tests for the early detection of cervical cancer. Currently, the Pap test is used in many countries to detect the presence of cancer cells in the cervix. However, the Cxbladder diagnostic test can detect the presence of certain proteins in the urine that indicate a cancerous condition, without the need for invasive procedures. The third pillar of Pacific Edge is the bladder cancer division. The Cxbladder test enables doctors to detect bladder cancer at an early stage. Currently, there are few effective screening methods for bladder cancer. However, the Cxbladder test can help detect bladder cancer at an early stage, improving treatment and cure rates. In addition to the three main areas, Pacific Edge also develops new diagnostic products for other types of cancer. These include cancers such as colon cancer, lung cancer, and kidney cancer, as well as rare cancers such as pancreatic cancer and esophageal cancer. Pacific Edge's products have already proven themselves in the medical community. They provide doctors and patients with an effective and cost-efficient way to detect cancer early. The company also conducts research and development to improve the accuracy and effectiveness of the tests offered. Pacific Edge is committed to expanding its business globally. It has already formed partnerships with some leading pharmaceutical and biotech companies to distribute its products on a global scale. The company has also established offices in Australia, the United States, and Singapore. In summary, Pacific Edge Ltd is a company specializing in the development and marketing of diagnostic tests for cancer. It focuses on the early detection of cancers such as prostate cancer, cervical cancer, and bladder cancer through the analysis of urine samples using state-of-the-art technologies. The company has established itself as a leading provider of cancer detection systems and conducts research and development to improve the accuracy and effectiveness of its products. Pacific Edge is committed to expanding its business globally and has already formed partnerships with leading companies in the pharmaceutical and biotech industry. Pacific Edge is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Pacific Edge's Return on Capital Employed (ROCE)

Pacific Edge's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Pacific Edge's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Pacific Edge's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Pacific Edge’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Pacific Edge stock

Return on Capital Employed (ROCE) of Pacific Edge is -121.79 % in 2025.

Return on Capital Employed (ROCE) of Pacific Edge changed from -61.47 % to -121.79 %, representing a 98.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Pacific Edge since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Pacific Edge with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Pacific Edge

All Key Metrics — Pacific Edge